ZIVO · Zivo Bioscience, Inc. · Financials
$0.67
At close · Nov 27
Return incl. dividend (before tax)
Going-concern doubt
— flagged Nov 14, 2025
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern within one year after the date the financial statements are issued.”View the 10-Q filed Nov 14, 2025
Market Cap
$16.53M
Shares
3.89M
Volume · Nov 27
226.8K
Avg daily vol (21 sessions)
42.21K
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$157.22K
+468.6%
FY2024
Net Income
-$13.38M
-72.1%
FY2024
Gross Margin
31.14%
-10.8pp
FY2024
Operating Margin
-8498.85%
+17768.8pp
FY2024
Diluted EPS
-$4.23
+8%
FY2024
Operating Cash Flow
-$4.31M
+25.6%
FY2024
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $209.03K | $157.22K | $27.65K | $0 | $0 | $20K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $103.89K | $82.73K | |
| $142.82K | $108.27K | $16.04K | $0 | — | — | — | — | — | — | — | — | $0 | $0 | $138.25K | $51.81K | |
| $66.21K | $48.95K | $11.61K | $0 | — | — | — | — | — | — | — | — | $0d | $0d | -$34.36Kd | $30.92Kd | |
| — | 31.14% | 41.99% | — | — | — | — | — | — | — | — | — | — | — | -33.07%d | 37.37%d | |
| $3.7M | $3.13M | $1.38M | $2.24M | $1.95M | $3.75M | $2.31M | $2.81M | $2.38M | $788.97K | $1.03M | $1.97M | $1.02M | $677.49K | $377.89K | $395.57K | |
| $4.83M | $10.28M | $5.9M | $6.49M | $6.69M | $4.82M | $4.08M | $1.35M | $2.13M | $832.24K | $963.3K | $1.04M | $1.19M | $938.2K | $603.1K | $1.24M | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | $967 | $967 | $966 | |
| — | — | — | — | $0 | $0 | $0 | $0 | $18.75K | $25K | $25K | $25K | $19.45K | $73.84K | $91.43K | — | |
| $8.52M | $13.41M | $7.27M | $8.73M | $8.65M | $8.58M | $8.35M | $6.13M | $6.33M | $3.49M | — | — | — | $2.08M | $2.04M | $4.14M | |
| — | — | — | — | — | — | — | — | — | $3.49M | $3.06M | $5.15M | $3.11M | $2.08M | — | — | |
| -$8.46M | -$13.36M | -$7.26M | -$8.73M | -$8.65M | -$8.56M | -$8.35M | -$6.13M | -$6.33M | -$3.49M | -$3.06M | -$5.15M | -$3.11M | -$2.08M | -$1.94M | -$4.06M | |
| — | -8498.85% | -26267.67% | — | — | -42778.38% | — | — | — | — | — | — | — | — | -1865.71% | -4909.09% | |
| — | — | — | — | -$8.65M | -$8.56M | -$8.35M | -$6.13M | -$6.31M | -$3.47M | -$3.03M | -$5.13M | -$3.09M | -$2.01M | -$1.85M | — | |
| — | — | $23.79K | $13.32K | $44.68K | $97.63K | — | — | — | -$35.49K | -$2400 | $515.61K | -$441.48K | -$141.73K | -$47.11K | -$13.96K | |
| — | — | — | -$13.32K | -$110.76K | -$550.05K | -$3.16M | -$8.5M | -$3.71M | -$2.57M | -$2.73M | — | — | -$1.17M | -$793.3K | -$3.06M | |
| -$8.49M | -$13.38M | -$7.78M | -$8.75M | -$8.76M | -$9.11M | -$11.51M | -$14.64M | -$10.04M | -$6.06M | -$5.79M | $680.81K | -$10.1M | -$3.25M | -$2.73M | -$7.12M | |
| — | -8513.44% | -28127.25% | — | — | -45528.64% | — | — | — | — | — | — | — | — | -2629.3% | -8609.82% | |
| USD/shares | -$2.13 | -$4.23 | -$4.60 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | — | — | — | — | 67.7M | 46.07M | 26.11M | 23.21M | 22.31M | 21.82M | 20.89M | 18.7M | 16.9M | — | — |
| shares | — | 3.17M | 1.69M | — | — | 67.7M | 46.07M | 26.11M | 23.21M | 22.31M | 21.82M | 30.37M | 18.7M | 16.9M | — | — |
d Gross profit for periods the company did not report it, or tagged its operating income as gross profit, is Revenue − Cost of Revenue. Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current portion of convertible debt | 2025-09-30 | USD 236,513 | 10-Q filed 2025-11-14 |
| Current portion of notes payable | 2025-09-30 | USD 139,223 | 10-Q filed 2025-11-14 |
| Noncurrent notes payable | 2025-09-30 | USD 11,663 | 10-Q filed 2025-11-14 |
| Operating lease liabilities | 2025-09-30 | USD 285,837 | 10-Q filed 2025-11-14 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
| Other notes payable | 2025-09-30 | USD 146,459 | 10-Q filed 2025-11-14 |
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.